Impact of NOTCH2 mutations on clinical outcome in SMZL. (A) Frequency of NOTCH2 mutations in SMZL, MALT-L, and other B cell proliferative disorders divided among the different domains of the NOTCH2 protein (color corresponds to domain in which mutations were located). For each separate disease, the number of samples with NOTCH2 mutations compared with total number of samples analyzed is displayed above each bar. (B) Cumulative probability of relapse, transformation or death from time of tissue diagnosis for patients with NOTCH2-mutated (red lines) and NOTCH2-wild-type (blue lines) SMZL. (C) Relapse-free survival from tissue diagnosis. (D) Overall survival from tissue diagnosis. The total number of patients in each analysis is displayed along the x-axes of each graph.